Applied Therapeutics, Inc.
Small molecule therapeutics targeting metabolic and cardiovascular disease pathways
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2016
- Latest Form D
- $100M, Mar 2024
- Total capital
- $189M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $189M
- 6 Form D · last Mar 2024
- 31 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 23 pending · first 2023
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$100M
- Private capital raisedForm D · SEC · 5th filing$30M
- Private capital raisedForm D · SEC · 4th filing$20M
- Private capital raisedForm D · SEC · 3rd filing$27.2M
- Private capital raisedForm D · SEC · 2nd filing$6M
- Private capital raisedForm D · SEC · 1st filing$6.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Shoshana ShendelmanResearcherExecutive Officer, DirectorLinked by 1 patent
- Adam HansardExecutive OfficerNamed in SEC Form D filings
- Catherine ThorpeExecutive OfficerNamed in SEC Form D filings
- Franklin BergerDirectorNamed in SEC Form D filings
- Jay S. SkylerDirectorNamed in SEC Form D filings
- Joel S. MarcusDirectorNamed in SEC Form D filings
Show all 11 people
- Les FuntleyderDirectorNamed in SEC Form D filings
- Mark VignolaExecutive OfficerNamed in SEC Form D filings
- Riccardo PerfettiExecutive OfficerNamed in SEC Form D filings
- Stacy J. KanterDirectorNamed in SEC Form D filings
- Teena LernerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 25- PendingInhibitors Of Aldose ReductaseUSPTOApplication 19414626
- GrantedInhibitors Of Aldose ReductaseUSPTOUS 12,528,823
- PendingAldose Reductase Inhibitors For Treating Sorbitol Dehydrogenase DeficiencyUSPTOApplication 18429719
Show all 25 patent records
- Inhibitors Of Aldose ReductaseApr 2, 2026 · Application 19414626Pending
- Inhibitors Of Aldose ReductaseJan 20, 2026 · US 12,528,823Granted
- Aldose Reductase Inhibitors For Treating Sorbitol Dehydrogenase DeficiencyJul 18, 2024 · Application 18429719Pending
- Compositions And Methods For Treating GalactosemiaNov 2, 2023 · Application 18158089Pending
- Aldose Reductase Inhibitors For Treating Sorbitol Dehydrogenase DeficiencyApr 20, 2023 · Application 18050627Pending
- Compositions And Methods For Treating GalactosemiaFeb 28, 2023 · US 11,590,131Granted
- Aldose Reductase Inhibitors For The Treatment Of Acute Respiratory Distress Syndrome, Acute Lung Inflammation/injury, Cardiac Injury And Anti-viral TherapyFeb 23, 2023 · Application 17951342Pending
- Aldose Reductase Inhibitors For Treatment Of Phosphomannomutase 2 DeficiencyJul 21, 2022 · Application 17715401Pending
- Methods For Treating Cutaneous AgingMar 10, 2022 · Application 17428917Pending
- Aldose Reductase Inhibitors And Uses ThereofApr 30, 2020 · Application 16607644Pending
- Inhibitors Of Aldose ReductaseApplication 62928735Pending
- Aldose Reductase Inhibitors For Treatement Of Phosphomannomutase 2 DeficiencyApplication 62912441Pending
- Methods For Treating Cutaneous AgingApplication 62804413Pending
- Compositions And Methods For Treating GalactosemiaApplication PCTUS2018044199Pending
- Aldose Reductase Inhibitors And Uses ThereofApplication PCTUS2018027960Pending
- Aldose Reductase InhibitorsApplication 62491243Pending
- Methods Of Treating Diabetic CardiomyopathyApplication 63708948Pending
- Aldose Reductase Inhibitors For Treating Sorbitol Dehydrogenase DeficiencyApplication PCTUS2021029286Pending
- Aldose Reductase Inhibitors For Treatment Of Phosphomannomutase 2 DeficiencyApplication PCTUS2020054607Pending
- Aldose Reductase Inhibitors for Treating Sorbitol Dehydrogenase DeficiencyApplication 63019738Pending
- Aldose Reductase Inhibitors for Treating Sorbitol Dehydrogenase DeficiencyApplication 63019186Pending
- Aldose Reductase Inhibitors For Anti-viral TherapyApplication 63006264Pending
- Aldose Reductase Inhibitors For Treatment Of Acute Respiratroy Distress Syndrome, Acute Lung Inflamation/injury And Cardiac InjuryApplication 63002538Pending
- Inhibitors Of Aldose ReductaseApplication PCTUS2020025928Pending
- Methods For Treating Cutaneous AgingApplication PCTUS2020017913Pending
Related companies, and why
- Dianthus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- AUXAGEN, INC.Similar federal contract value in Biotech · null in contracts
- ANOVAC, INC.Similar federal contract value in Biotech · null in contracts
- AVANT IMMUNOTHERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Leivis BioSimilar federal contract value in Biotech · null in contracts
- AGENOVIR CORPORATIONSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .